Niraparib,abiraterone,Prednisone
Janssen
['crpc', 'biomarker', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'niraparib']
magnitude demonstrates 45% reduction in risk of progression or death in patients treated with niraparib + abi, with trend of os, underlining the clear need for a biomarker-driven testing and treatment approach in mcrpc #gu23 #guasco23 
Medical Oncologist, Chair Southern Alberta GU Tumour Group, Tom Baker Cancer Centre. Opinions are my own.